This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Amid ongoing concern over the quality of medicines made in India, a major supplier of genericmedicines was seen removing three truckloads of “scrap materials” from a facility that was being inspected last month by the Food and Drug Administration.
“Tweak in policy is mooted,” the document from the prime minister’s office said, adding that “important things” had been “overlooked” It did not elaborate. Increased testing of cough syrups as well as of raw materials for drugs in general is one of the steps being considered, said the source.
India Pharma Inc, hailed for its prowess in the production of high-quality genericmedicines, now needs to shift from a conventional, volume-based business strategy to a value-based approach to keep it up its growth momentum. In this context, finding the right opportunities and understanding the challenges has become crucial.
The pundits are unanimous in their response – changes in the US generic drug market. The US is the biggest market for genericmedicines (~90 per cent of prescriptions are fulfilled by generic drugs). What is the reason behind this lull as far as the Indian life science companies are concerned?
This is long overdue as the current tender process has been one of the root causes for the decline in Europe’s essential medicines manufacturing due to the sole focus on price, to the exclusion of other factors like quality and sustainability of supply.
Drug Tariff Basics The NHS Drug Tariff is a crucial document that sets out pharmacy remuneration and reimbursement rates across England and Wales, acting as the foundation for pharmacy business operations. Without this careful management, you risk dispensing at a loss, especially when dealing with high-volume or costly medications.
Medicines that do not fall into one of the three groups of existing patented medicines will be regulated as new patented medicines and assigned to either Category I or Category II. Medicines falling below these thresholds, as well as biosimilars and generics, will be classified as Category II.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content